LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
ELI LILLY & Co
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1240.34−16.69 (-1.33%)
Close on Oct 19, 2026
- Market cap
- $1.11T
- P/E (TTM)
- 41.6
- Dividend yield
- 0.50%
ELI LILLY & Co revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenue | $74.49B | $67.81B | $60.96B | $54.68B | $48.92B | $44.55B | $40.75B | $37.01B | $33.75B | $30.37B | $28.81B | $26.86B | 93.5% | +52.3% |
| Collaboration and other revenue | $5.18B | $4.44B | $4.22B | $4.74B | $4.33B | $4.45B | $4.30B | $3.85B | $5.18B | $5.56B | $5.31B | $5.21B | 6.5% | +19.5% |
| Jardiance | $4.07B | $3.53B | $3.43B | $3.86B | $3.59B | $3.67B | $3.34B | $2.94B | $2.96B | $2.85B | $2.75B | $2.56B | 5.1% | +13.5% |
| Trajenta | – | – | – | – | – | – | – | $359.40M | $362.90M | $389.90M | $386.90M | $375.30M | – | – |
| Basaglar | – | – | – | – | – | – | $676.90M | $685.20M | $703.20M | $676.60M | $728.30M | $744.80M | – | – |
| Collaboration and other revenue associated with prior period transfers of intellectual property | – | – | – | – | – | – | – | – | – | – | $191.60M | $119.20M | – | – |
| Olumiant | – | – | – | – | – | – | $957.40M | $939.30M | $919.90M | $911.10M | $922.60M | $885.00M | – | – |
| COVID-19 antibodies | – | – | – | – | – | – | – | – | – | – | $0 | $34.50M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $50.71B | $47.11B | $43.48B | $39.63B | $36.15B | $33.17B | $30.38B | $27.80B | $25.35B | $23.05B | $21.79B | $19.99B | 63.7% | +40.3% |
| Outside U.S. | $28.96B | $25.14B | $21.70B | $19.78B | $17.11B | $15.83B | $14.67B | $13.06B | $13.57B | $12.88B | $12.33B | $12.08B | 36.3% | +69.2% |
| Europe | $14.36B | $12.81B | $11.56B | $10.91B | $9.04B | $7.87B | $6.92B | $5.81B | $6.75B | $6.52B | $6.18B | $5.91B | 18.0% | +58.8% |
| Rest of world | $9.53B | $7.83B | $6.06B | $4.93B | $4.35B | $4.38B | $4.27B | – | – | – | – | – | 12.0% | +118.9% |
| China | $2.67B | $2.19B | $1.95B | $1.91B | $1.81B | $1.73B | $1.66B | $1.61B | $1.54B | $1.54B | $1.54B | $1.51B | 3.3% | +47.7% |
| Japan | $2.41B | $2.30B | $2.13B | $2.04B | $1.91B | $1.85B | $1.82B | $1.70B | $1.66B | $1.65B | $1.67B | $1.63B | 3.0% | +26.0% |
| Other foreign countries | – | – | – | – | – | – | – | $3.95B | $3.62B | $3.17B | $2.95B | $3.02B | – | – |
From the segment and revenue-disaggregation notes of Eli Lilly's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.